CONFLICT OF INTEREST
ONCOLOGY
YKK has served as a consultant for ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, and Merck (MSD). MHR received honoraria from DAEHWA Pharmaceutical, Bristol Myers Squibb, Lilly, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Novartis, Daiichi Sankyo, and AstraZeneca, and served as a consultant for DAEHWA Pharmaceutical, Bristol Myers Squibb, Lilly and Ono Pharmaceutical. KHY received honoraria from Amgen, Boehringer Ingelheim, Bayer, BMS, Merck Serono, Eli Lilly, Ono Pharmaceutical, Takeda, MSD, Daiichi Sankyo, and AstraZeneca. YHK has received research grants from MSD, ONO Pharmaceuticals, BMS, Incyte, Macrogenics, Roche, and Merck. No other author has a potential conflict of interest to declare that is relevant to this article.